fatty liver

Non-alcoholic fatty liver disease encompasses a spectrum from simple steatosis to metabolic-associated steatohepatitis and cirrhosis, affecting roughly 25% of the global population. It is closely linked to metabolic syndrome, obesity, and type 2 diabetes, and is the fastest-growing indication for liver transplantation. Several NASH therapies, including THRβ agonists, FXR agonists, and GLP-1 receptor agonists, have advanced to late-stage clinical trials.